Page 85 of Artifice
The headmaster from Oakridge Academy?
Brianna’s dad.
The man Olive’s dad had ruined.
Would he remember Olive Sterling, the quiet girl who disappeared the same night the school lost millions?
Sheffield’s eyes flickered over her with polite interest then away.
Olive released a silent breath. Twelve years was a long time.
She’d been a child then, and she looked different now. She was all grown up.
He shouldn’t recognize her.
Still, anxiety coiled in her stomach.
Director Ingraham cleared her throat. “Mr. Morgan will address the financial statements first, then we’ll discuss the success metrics of our therapeutic approach.”
As Morgan droned on about budgets and allocations, Olive scanned the other board members.
Mrs. Whitmore kept checking her phone under the table. Dr. Chen’s expression remained impassive, though his fingers drummed nervously against his leather portfolio. Principal Denarau nodded at appropriate intervals, his charisma on full display.
“Which brings us to the specialized equipment expenses,” Morgan was saying. “As you can see on page twelve, our investment in the new ‘pharmaceutical compliance program’ has significantly improved student outcomes.”
Olive flipped to the page, noting the vague language and enormous sums listed. This had to be connected to what Abe had told her—the pills they were forcing on students.
“If I may,” she interrupted. “What metrics are you using to measure these improvements? I’m curious about your definition of ‘success.’”
Director Ingraham’s smile tightened. “Dr. Wells can speak to that.”
Wells leaned forward. “Reduced incidents of defiance, improved focus, greater amenability to therapeutic intervention.” His gaze lingered on Olive. “We’ve developed quite a remarkable approach to behavioral modification.”
Something in his tone made the hair on Olive’s neck stand up.
She pressed on. “And the pharmaceuticals involved—are these FDA-approved treatments?”
A heavy silence fell over the room.
Chen and Whitmore exchanged glances.
“They’re classified as supplements,” Wells replied. “Proprietary formulations that don’t require FDA oversight.”
“Fascinating,” Olive said. “My foundation typically requires independent verification of?—”
“Excuse me,” Sheffield interrupted, his head tilted. “Have we met before, Ms. Bettencourt? You seem remarkably familiar.”
Every muscle in Olive’s body tensed. “I don’t believe so.”
“No, I’m certain . . .” His eyes narrowed.
Olive held her breath as she waited to see if he remembered.
The room seemed to close in around Olive.
Denarau and Ingraham exchanged confused looks.
“I can’t place you now,” Sheffield finally said. “Maybe it will come to me.”
Table of Contents
- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Page 41
- Page 42
- Page 43
- Page 44
- Page 45
- Page 46
- Page 47
- Page 48
- Page 49
- Page 50
- Page 51
- Page 52
- Page 53
- Page 54
- Page 55
- Page 56
- Page 57
- Page 58
- Page 59
- Page 60
- Page 61
- Page 62
- Page 63
- Page 64
- Page 65
- Page 66
- Page 67
- Page 68
- Page 69
- Page 70
- Page 71
- Page 72
- Page 73
- Page 74
- Page 75
- Page 76
- Page 77
- Page 78
- Page 79
- Page 80
- Page 81
- Page 82
- Page 83
- Page 84
- Page 85 (reading here)
- Page 86
- Page 87
- Page 88
- Page 89
- Page 90
- Page 91
- Page 92
- Page 93
- Page 94
- Page 95
- Page 96
- Page 97
- Page 98
- Page 99
- Page 100
- Page 101
- Page 102
- Page 103
- Page 104